1. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
   Ines De Pauw et al, 2019, Cancers CrossRef
2. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
   Sandrine Hiret et al, 2018, Investigational New Drugs CrossRef
3. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
   Gustavo A. Arias-Pinilla et al, 2020, Scientific Reports CrossRef
4. Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
   Said Abdullah Khelwatty et al, 2019, Oncotarget CrossRef
5. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
   Pei San Yee et al, 2019, Targeted Oncology CrossRef